Cashmaker's hot stocks and trading

[cashmaker]

Time to buy MPS, which has the best financial background in my portfolio. MPS with no

Time to buy MPS, which has the best financial background in my portfolio. MPS with no debt, strong EBITA compare to peers in the industry, impressive balance sheet. IT outsource will keep going as the hottest sector in the coming year. MPS's target is $16 within 3 monthes and $20 in a 12 monthes period. Buy more shares here. This week, MPS shows a typical selloff on profit taken, however, $14 level hell no as its peak. Higher target will come soon. I am bullish here on MPS--low risk as well as large appreciation space.

[cashmaker]

Looking forward IM's COO presentation. Will be a strong and good factor add to IM's s

Looking forward IM's COO presentation. Will be a strong and good factor add to IM's stock price.

Ingram Micro Executive to Present at Upcoming Investor Conference


12-21-05 04:03 PM EST |

/PRNewswire-FirstCall/ -- Ingram Micro Inc. (NYSE: IM), the world's largest technology distributor, announced today that its president and COO will present at the following investor conference in January

[cashmaker]

CHB's CEO interviewed by WSJ yesterday, they mentioned the strong relationship with F

CHB's CEO interviewed by WSJ yesterday, they mentioned the strong relationship with FEMA (government) for rebuilding the Katrina disaster area. Demand side on factory-built home is huge due to the Hurricane.

Champion Enterprises -- Chairman & CEO Interview
Dylan Ratigan

DYLAN RATIGAN, CNBC ANCHOR: Now on to a different type of homebuilding, modular and manufactured housing. The industry has gone through its share of problems over the past few years, but there now appear to be some signs of improvement. For more on the turn around, we`re joined by William Griffiths. He`s the president and CEO of Champion Enterprises. It`s the nation`s largest producer of modular homes.

And Mr. Griffiths, make the distinction for us. What is a modular home?

WILLIAM GRIFFITHS, PRESIDENT & CEO, CHAMPION ENTERPRISES: A modular home is simply built to exactly the same codes and specifications as a site- built home. We just build it in a factory.

RATIGAN: So it`s built ahead of time and then delivered and assembled in pieces, that`s the distinction?

GRIFFITHS: Exactly.

RATIGAN: Why was there trouble in that business, in your business, at a time when the broader housing market was really cycling up?

GRIFFITHS: Well, first of all, there really hasn`t been trouble in the modular part of our business; it`s the traditional manufactured housing industry or better known as mobile homes. That`s the segment of the industry that`s had difficulty since 1998. And that was primarily driven by financing concerns not by the manufacturing sector of the business.

RATIGAN: The modular home business, is it parallel to the site built home business? In other words, do you price similarly? Are the homes similar? And why would an individual make the distinction or the choice to buy a modular home versus a site built home if they`re a new home buyer?

GRIFFITHS: The primary proposition for someone to build a modular home as opposed to a site built home is speed and quality. Typically, from signing a contract to move in date for a modular home is 90 days. Very difficult for site builders to match that and because our homes are designed to go down the highway at 60 miles an hour, typically they`re the higher level of quality as well.

RATIGAN: And what is the price range of the modular home?

GRIFFITHS: They can vary from a very entry level home, which of course, is the start point in our industry, perhaps around $100,000 up to multi- million dollar homes. We, in fact, built a home in Colorado that`s 6,800 square feet and sold for a million 3.

RATIGAN: Tell us about your relationship with FEMA and your efforts in New Orleans.

GRIFFITHS: Well, you know, we took an order from FEMA for 2,000 units for temporary housing down in New Orleans. They have been very cooperative to work with under extremely difficult conditions. You know the logistics involved in gathering and trying to disperse all these houses is a massive undertaking, and they`ve been very, very cooperative to work with.

RATIGAN: The home build-out is funded by the government, is that correct?

GRIFFITHS: That is correct. I think in terms of permanent housing in New Orleans, you know there`s still a tremendous amount of work to be done in that region in terms of planning and making sure the infrastructure is in place. So I think in terms of permanent rebuilding, it`s likely to be the second half of next year before we see really any benefits.

RATIGAN: All right. Mr. Griffiths, a pleasure to have you with us this afternoon. Thank you for it. We`ll see you in a little bit when you ring the closing bell to celebrate your company`s 10th anniversary listing on the big board.

[cashmaker]

Big news to LSI, new technology. California Inventors Develop Semiconductor Device Fa

Big news to LSI, new technology. California Inventors Develop Semiconductor Device Fabrication Method. The patent has been assigned to LSI Logic Corp., Milpitas, Calif.


ALEXANDRIA, Va., Dec. 22 -- Helmut Puchner of Santa Clara, Calif., and Gary K. Giust of Cupertino, Calif., have developed a method for forming a silicon germanium complimentary metal oxide semiconductor channel in a semiconductor device.

According to the U.S. Patent & Trademark Office, the invention relates to a "method for fabricating a semiconducting device on a substrate, where the improvement includes forming a strained silicon germanium channel layer on the substrate. A gate insulation layer is formed on top of the strained silicon germanium channel layer, at a temperature that does not exceed about eight hundred centigrade. A gate electrode is formed on top of the gate insulation layer, and the gate electrode is patterned. A low dose drain dopant is impregnated into the substrate, and activated with a first laser anneal."

An abstract of the invention, released by the Patent Office, said: "A source-drain dopant is impregnated into the substrate, and activated with a second laser anneal. After the step of activating the low dose drain dopant with the first laser anneal, an insulating layer is formed around the gate electrode, at a temperature that does not exceed about eight hundred centigrade, and a spacer is formed around the gate electrode. The spacer is formed of a material that is reflective to the second laser anneal. Thus, standard materials for the spacer, such as silicon oxide or silicon nitride are not preferred for this application, because they tend to be transparent to the laser beam emissions."

The inventors were issued U.S. Patent No. 6,977,400 on Dec. 20.

The patent has been assigned to LSI Logic Corp., Milpitas, Calif.

The original application was filed on Feb. 18, 2003, and is available at: http://patft.uspto.gov/netacgi/nph-P...ISD/12/20/2005 .

[cashmaker]

Increase my weight of NDN in my portfolio. Post-Christmas Sales Keep Shoppers Buying,

Increase my weight of NDN in my portfolio. Post-Christmas Sales Keep Shoppers Buying, Retail stores stocks all rally today. NDN undervalued, no downside risk, it has been on the bottom for almost 2 months, from TA, it is perfect. Retail sector play here.

[cashmaker]

Deal between Siemens and EMC:

Deal between Siemens and EMC:
Siemens to offer information lifecycle products to healthcare market 2005 DEC 31 - (NewsRx.com) -- Siemens Medical Solutions, a medical equipment and information technology company, and EMC Corporation, an information management and storage company, have announced a reseller agreement enabling Siemens to offer EMC information lifecycle management products and solutions to the healthcare market.

Siemens will offer EMC Symmetrix, EMC CLARiiON and EMC Centera networked storage systems and platform software with its medical imaging software, Soarian health information system, and syngo suite of radiology information system (RIS) and picture archiving and communication systems.

The combination of Siemens' and EMC's product portfolios will provide healthcare organizations with a tiered information infrastructure to implement an ILM strategy.

Siemens Medical Solutions of Siemens AG has headquarters in Malvern, Pennsylvania and Erlangen, Germany.

[cashmaker]

HLTH buy back 20% (60 Million shares) of its outstanding shares, very good sign to it

HLTH buy back 20% (60 Million shares) of its outstanding shares, very good sign to its stock price. Like Peter Lynch said in his book: there are many reasons that the insiders sell their shares, but there is only one reason they buy: the stock is undervalued and is cheap. We will see HLTH easily to $10

Finance; Emdeon announces commencement of its tender offer

2005 DEC 25 - (NewsRx.com) -- Emdeon Corp. (HLTH) announced that it has commenced its tender offer to purchase up to 60,000,000 shares of its common stock at a price per share of $8.20.

The number of shares proposed to be purchased in the tender offer represents approximately 17.4% of the company's currently outstanding shares. The last reported sales price per share of the company's common stock on the Nasdaq national market on November 22, 2005, was $7.75 per share.

The company's directors and executive officers have advised the company they do not intend to tender any of their shares in the tender offer.

The tender offer is scheduled to expire December 21, 2005, unless extended by the company. Tenders of shares must be made on or prior to the expiration of the tender offer and may be withdrawn at any time on or prior to the expiration of the tender offer.

The tender offer is subject to a number of terms and conditions described in the offer to purchase that is being distributed to stockholders, including that a minimum of 27,500,000 shares be properly tendered and not properly withdrawn in the offer.

On the terms and subject to the conditions of the tender offer, the company's stockholders will have the opportunity to tender some or all of their shares at a price of $8.20 per share. If stockholders properly tender and do not properly withdraw more than 60,000,000 shares, the company will purchase shares tendered by those stockholders owning fewer than 100 shares, without pro ration, and all other shares tendered will be purchased on a pro rata basis, subject to the conditional tender offer provisions described in the offer to purchase that is being distributed to stockholders.

Stockholders whose shares are purchased in the tender offer will be paid $8.20 per share, net in cash, without interest, promptly after the expiration of the tender offer period.

[cashmaker]

RNAI a strong buy here,Bio analysts recommend it last week with target $8-$10 in 2006

RNAI a strong buy here,Bio analysts recommend it last week with target $8-$10 in 2006. RNAI made a significant progress Hepatitis C antiviral program,and completed its preclinical evaluation of the efficacy of Sirna-AV34 and has begun cGMP manufacturing for its Phase I clinical studies. Analysts said if this drug pass the phase III, it will dominant the Hepatitis C drug market and it is a revolutionary progress on Hepatitis C therapy.

Following is the article last week on Morningstar, very positive report on RNAI Hepatitis C research.

Sirna Therapeutics Selects Development Candidate for Its Hepatitis C Antiviral Program


12-21-05 08:03 AM EST | Systemically Delivered siRNA Designed to Dramatically Reduce Drug Resistant Variants

/PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. (Nasdaq: RNAI), a leading RNAi therapeutics company, announced today that it has selected Sirna-AV34, a systemically delivered, chemically modified short interfering RNA (siRNA) compound, as its candidate for advancement to human clinical testing against Hepatitis C virus. Sirna completed its preclinical evaluation of the efficacy of Sirna-AV34 and has begun cGMP manufacturing for its Phase I clinical studies. Sirna expects to initiate IND-enabling toxicology studies in the first quarter of 2006 followed by the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) by the fourth quarter of 2006.

Sirna-AV34 is a systemically delivered, nanoparticle-based therapeutic targeting the Hepatitis C virus. The compound consists of multiple individual, chemically modified, siRNA sequences which target highly conserved sequences in the Hepatitis C viral genome. Sirna-AV34 is designed to inhibit viral replication and dramatically reduce the selection of drug resistant mutant variants. The design principles used in Sirna-AV34 were validated by demonstrating reduction in escape mutation frequency in the Hepatitis C virus sub-genomic replicon system in vitro. No existing therapeutic approach has the potential to broadly inhibit Hepatitis C viral replication while reducing the probability of drug resistant variants.

"We are extremely pleased by the significant progress of our Hepatitis C antiviral program," stated Sirna Senior Vice President and Chief Scientific Officer, Barry Polisky, PhD. "The selection of Sirna-AV34 as our clinical candidate reflects two major accomplishments of our research team. The first is the design, chemical modification and synthesis of a stable and potent siRNA compound which is effective broadly against the Hepatitis C virus. The second is the development of a proprietary nanoparticle delivery technology capable of efficient and specific delivery of the siRNA compound to hepatocytes. These two achievements have provided us with a unique opportunity to bring this groundbreaking therapy to the clinic."

Sirna has completed its preclinical evaluation including demonstration of systemic efficacy in both rodent and non-human primate animal models. As previously reported in a rodent model of Hepatitis B virus used as a surrogate for Hepatitis C virus, Sirna demonstrated that a chemically optimized and encapsulated siRNA had significant antiviral activity and prolonged duration of effect in vivo. Recent data from a non-human primate model of Hepatitis C replication demonstrated that Sirna's systemically delivered siRNA compound dramatically suppressed Hepatitis C viral titers via an RNA interference mechanism.

"We are very excited to be moving a systemically delivered siRNA towards the clinic," stated Roberto Guerciolini, MD, Senior Vice President and Chief Medical Officer. "Since the current treatments for chronic Hepatitis C remain highly unsatisfactory, we believe that the application of an siRNA compound targeting multiple components of the viral genome will result in a significant advancement in the treatment of this disease."

Sirna-AV34 will be manufactured at Sirna's cGMP facilities in Boulder, Colorado for both Phase I enabling toxicology studies and Phase I human clinical testing.

About Sirna Therapeutics

Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis B and C, dermatology, asthma, Huntington's disease, diabetes and oncology. Sirna Therapeutics has presented interim Phase 1 clinical trial data for its most advanced compound, Sirna-027, a chemically optimized siRNA targeting the clinically validated vascular endothelial growth factor pathway to treat AMD. Sirna-027, which has been partnered with Allergan, Inc., has been shown to be safe and well tolerated with a trend toward visual acuity improvement and demonstrated biological activity. Sirna has a leading intellectual property portfolio in RNAi with 45 issued patents and over 250 pending applications worldwide. More information on Sirna Therapeutics is available on the Company's web site at http://www.sirna.com.

Safe Harbor Statement

Statements in this press release which are not strictly historical are "forward-looking" statements which should be considered as subject to many risks and uncertainties. For example, Sirna's ability to develop a treatment for Hepatitis C will require additional, much more costly clinical trials, the results of which are highly uncertain. Moreover, Sirna's ability to develop products and operate as a going concern requires significant cash to fund its operating programs. Additional risks and uncertainties include Sirna's early stage of development and short operating history, Sirna's history and expectation of losses and need to raise capital, Sirna's need to obtain clinical validation and regulatory approval for products, Sirna's need to obtain and protect intellectual property, risk of third-party patent infringement claims, Sirna's need to attract and retain qualified personnel, Sirna's need to engage collaborators, availability of materials for product manufacturing, the highly competitive nature of the pharmaceutical market, the limited trading volume and history of volatility of Sirna's common stock, Sirna's concentration of stock ownership, and risks from relocating Sirna headquarters. These and additional risk factors are identified in Sirna's Securities and Exchange Commission filings, including the Forms 10-K and 10-Q and in other SEC filings. Sirna undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

[cashmaker]

The RNAi Market is Predicted to Be Worth $850 Million by 2010 and is Expected to Furt

The RNAi Market is Predicted to Be Worth $850 Million by 2010 and is Expected to Further Increase to $1.2 Billion by 2015

DUBLIN, Ireland --(Business Wire)-- Dec. 15, 2005 -- Research and Markets (http://www.researchandmarkets.com/reports/c1589) has announced the addition of the Jain PharmaBiotech report: RNAi -- Technologies, Markets and Companies to their offering.



The markets for RNAi are difficult to define as no RNAi-based product is in clinical development yet. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. It is estimated to be $400 million currently in 2005,$850 million by the year 2010 and $1.2 billion by the year 2015. The value of the drug discovery market based on RNAi can be assessed at $650 million in the year 2005, increasing to $1 billion in the year 2010 and $1.5 billion in 2015. Even if a few products get into the market by the year 2010, this market will expand to $3.5 billion based on revenues from sales of RNAi- based drugs and increase further to $5.9 billion in 2015. Markets are also analyzed according to breakdown of technologies and use of siRNAs, miRNAs, etc.

Profiles of 126 companies involved in developing RNAi technologies are presented along with 105 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Approximately 18 of these are developing RNAi-based therapeutics. The bibliography contains selected 300 publications that are cited in the report. The text is supplemented with 25 tables and 7 figures.

RNA interference (RNAi) or gene silencing involves the use of double stranded RNA (dsRNA). Once inside the cell, this material is processed into short 21-23 nucleotide RNAs termed siRNAs that are used in a sequence-specific manner to recognize and destroy complementary RNA. The report compares RNAi with other antisense approaches using oligonucleotides, aptamers, ribozymes, peptide nucleic acid and locked nucleic acid.

Various RNAi technologies are described, along with design and methods of manufacture of siRNA reagents. These include chemical synthesis by in vitro transcription and use of plasmid or viral vectors. Other approaches to RNAi include DNA-directed RNAi (ddRNAi) that is used to produce dsRNA inside the cell, which is cleaved into siRNA by the action of Dicer, a specific type of RNAse III. MicroRNAs are derived by processing of short hairpins that can inhibit the mRNAs. Expressed interfering RNA (eiRNA) is used to express dsRNA intracellularly from DNA plasmids.

Delivery of therapeutics to the target tissues is an important consideration. siRNAs can be delivered to cells in culture by electroporation or by transfection using plasmid or viral vectors. In vivo delivery of siRNAs can be carried out by injection into tissues or blood vessels or use of synthetic and viral vectors.

Because of its ability to silence any gene once the sequence is known, RNAi has been adopted as the research tool to discriminate gene function. After the genome of an organism is sequenced, RNAi can be designed to target every gene in the genome and target for specific phenotypes. Several methods of gene expression analysis are available and there is still need for sensitive methods of detection of gene expression as a baseline and measurement after gene silencing. RNAi microarray has been devised and can be tailored to meet the needs for high throughput screens for identifying appropriate RNAi probes. RNAi is an important method for analyzing gene function and identifying new drug targets that uses double-stranded RNA to knock down or silence specific genes. With the advent of vector-mediated siRNA delivery methods it is now possible to make transgenic animals that can silence gene expression stably. These technologies point to the usefulness of RNAi for drug discovery.

RNAi can be rationally designed to block the expression of any target gene, including genes for which traditional small molecule inhibitors cannot be found. Areas of therapeutic applications include virus infections, cancer, genetic disorders and neurological diseases. Side effects can result from unintended interaction between an siRNA compound and an unrelated host gene. If RNAi compounds are designed poorly, there is an increased chance for non-specific interaction with host genes that may cause adverse effects in the host.

Regulatory, safety and patent issues are discussed. There are no major safety concerns and regulations are in preliminary stages as the clinical trials are just starting. Many of the patents are still pending. -0- *T Topics Covered: Executive Summary 1 Technologies for suppressing gene function 2 RNAi Technologies 3 MicroRNA 4 Methods of delivery in RNAi 5 RNAi in Research 6 RNAi in drug discovery 7 Therapeutic applications of RNAi 8 Safety, regulatory and patent issues 9 Markets for RNAi Technologies 10 Companies involved in RNAi Technologies 11 References *T

[cashmaker]

Comment on RNAI's new technology and products. You might not know how big the RNAi ma

Comment on RNAI's new technology and products. You might not know how big the RNAi market is and how well it can be used in treating hepatitis B and C, dermatology, asthma, Huntington disease, diabetes and oncology and AIDS and more. The RNAi Market is Predicted to Be Worth $850 Million by 2010 and is Expected to Further Increase to $1.2 Billion by 2015. When the time RNAi announce its new drug, those big firms, such as VRX, SGP have to use its license.

Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis B and C, dermatology, asthma, Huntington disease, diabetes and oncology.

Sirna Therapeutics has presented interim phase I clinical trial data for its most advanced compound Sirna-027, a chemically optimized siRNA targeting the clinically validated vascular endothelial growth factor pathway to treat AMD.

Recently, even government pay attention to RNAi tech.Alnylam Pharmaceuticals Inc.received initial government funding to develop RNA interference therapy for pandemic influenza. You can ask any university biology department, there are tons of researchers use RNAi tech on their research.Or take a look at biology literature, it shows how bright the RNAi future is.

The reason I recommend RNAI is this week biotech analysts raise RNAI's target to $8-$10 and wrote a very positive report on RNAI's product. Sirna expects to initiate IND-enabling toxicology studies in the first quarter of 2006 followed by the filing of an Investigational New Drug (IND) application with the U.S. FDA by the fourth quarter of 2006.

This is not a penny stock and is not a micro biotech company. This company's business is huge and has tremedous potential in developing new drug to cure Hepatitis, HIV, Asthma, Oncology, etc.

[Websman]

You have me interested in RNAI. Judging from you excellent stock picking skills, I'd say this one should be a winner!

Thanks for the info Cash.

[spikefader]

RNAI looks like a good short to me.

[Websman]

RNAI looks like a good short to me.

I haven't had time to actually check the charts yet, but I'll definitely forget about taking this one long. lol

[cashmaker]

Like Peter Lynch said: "Buy what you buy.", Here is what customer say about NDN:

Like Peter Lynch said: "Buy what you buy.", Here is what customer say about NDN:

Bargain Hunters Head to Dollar StoresDollar Stores Attract All Income Levels
Dollar stores are a penny pincher's paradise. (ABC NEWS)

Dec. 27, 2005 — Dollar stores are growing in popularity, attracting more than the standard penny-pinching crowd.

Seventy-five percent of American households shop at these discounters, according to a survey by global management consulting and market research firm Retail Forward. One-third of all dollar-store shoppers have incomes of more than $50,000, according to a Retail Forward survey. And many have incomes far above that. There are even dollar stores in ritzy Beverly Hills, Calif.



Year-End Tax Tips
Hollywood Stars Still Dancing at 86
Kenya's Hippo, Tortoise Mark Year Together
The deep-discount, corner-store concept was born in 1955 when Dollar General store opened. Dollar General is considered the first dollar store.


"I shop here for financial reasons," said Gwendolyn Johnson, who checks supermarket prices before buying at her local dollar store. "It saves me a lot of money, and I have more food in my house for my kids to eat."

ABC News compared eight brand-name items at a Los Angeles 99 Cents Only store with identical ones sold at a supermarket chain. The bill at 99 Cents Only came to $7.92, but the same products at the grocery store totalled $14.78.

Alissa Alhman, a buyer for 99 Cents Only, said that her chain could offer the lower prices because it purchased the products on a closeout, meaning the distributor sells the item on deep discount to reduce inventory.

Avocados to aspirin, batteries to bagels, and computer cables to clothing, the merchandise moves fast — which translates to big business for the dollar stores. They have among the largest profit margins in the industry.

"They do billions of dollars every year, and each one of these companies has found neighborhoods where they do well," said Dan Butler, vice president of retail operations for the National Retail Federation. "And they know their customers and they know where they are going to find their customers."

From coast to coast, the biggest chains have grown to nearly 17,000 with $17 billion in combined revenues.

"We have two types of customers," said Eric Schiffer, chief executive officer of 99 Cents Only stores. "We have lower-income, blue-collar customers who rely on this store. But the other group of customers are more mid to upscale folks who really just enjoy getting a great deal. They have a lot of fun in the store."

[cashmaker]

RNAi technology is discussed all over the place, including magazine, web, academic fi

RNAi technology is discussed all over the place, including magazine, web, academic field,since it's the next hope for cure HIV, Hepatitis B, C, Huntington's disease. Institutions holding almost 50% of RNAI's share which is unsusal for a small biotech firm, I believe those biotech analysts are very optimistic on Sirna's techology and potential new drugs. I study the wall street webcasting on RNAI which demenstrate their strong results of Phase I and how powerful the new tech on those disease. Here is the link: http://wsw.com/webcast/rrshq7/rnai/

Do you own study on RNAi on google and you will find that people have strong interest in this new technology:

http://www.allbusiness.com/periodicals/topic/2637969-1-2.html

Something is brewing, maybe the good results of their clinical study or strong expectation of their Phase II. It is not usual that analysts strong recommend a small biotech company like that, there must be something going on. In RNAI last week after analysts boost their optimistism on it. RNAi is low float stocks which high institutions interest in it, will easily fly when the news come.